ArticleIndian journal of surgical oncology2026
Rectal Neuroendocrine Tumours: A 10-Year Review of Clinical Presentation, Pathological Features, and Treatment Outcomes from a Tertiary Care Cancer Centre in Western India.
Article in Indian journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rectal neuroendocrine tumours are rare but increasing worldwide. However, there is limited data from regions like the Indian subcontinent, where clinical presentations and outcomes may differ due to unique demographic and biological factors. This study aimed to characterize rectal neuroendocrine tumours in our region, focusing on clinic-pathological presentation, and treatment outcomes. This was an observational single-centre retrospective cohort study from a high-volume tertiary care centre in Western India. Sixty-five consecutive patients with rectal neuroendocrine tumours treated between 2013 and 2023 were included. The main outcome measures were overall survival and disease-free survival. Secondarily, we tried to evaluate the impact of pathological grade and surgery-type on survival outcomes. The median age at diagnosis was 50 years, younger than the global median (56-57 years), with a male predominance (80%). Majority of patients were symptomatic and had locally advanced disease, with 64% showing metastatic spread. Pathologically, 82% of tumours were classified as Grade II/III, with a high median tumour size (3.7 cm) and elevated serum Chromogranin A levels. Multimodal treatment, including surgery and adjuvant therapies, was utilized for most patients. Of the 41.5% who underwent surgery, 70% had sphincter-preserving procedures. The median overall survival for the entire cohort was not reached, but 3-year and 5-year overall survival rates were 91% and 85%, respectively. Grade III tumours had significantly poorer outcomes, with a 5-year survival of 57% compared to nearly 100% in Grade I and II tumours. Apart from its retrospective nature, our study may have limited generalizability due to potential referral bias, and the lack of detailed pathological subclassification would be an opportunity for future research. As the first study from the Indian subcontinent we highlight how our patients presented at a younger age with advanced, aggressive disease. Multimodal approach could improve outcomes even in advanced disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.